Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (710)	5/4/1998 9:08:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

Sorry about the jargon Cohort= group. in phase 2 study of hu211 there are now 3 groups, group 1 low dose and placebo(placebo = no medication, but is looks like you are getting medication. so as long as the study is blinded no one knows who gets what.untill they break the code.)group 2 enrollment completed but long term follow up still on, and third group much higher dose, to see if there are side affects at higher dose how safe it is and if with higher dose you get more effect. this last group is getting on now. Study in Israel done to FDA specification, it does not have to be repeated in USA. It is done in Israel for number of reason. It is Israeli medication. They got some money from Israeli government and thus have to do it in Israel. And study is much much cheaper in Israel. Phase 3 study will be done in USA may be Israel be another center. Phase 3 study will be in multiple areas. Even in Israel it is done in number of Trauma centers. Time frame should be same.